Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Earns Buy Rating from Ladenburg Thalmann Financial Services

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “buy” rating restated by investment analysts at Ladenburg Thalmann Financial Services in a note issued to investors on Thursday, September 21st. They currently have a $146.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $90.00. Ladenburg Thalmann Financial Services’ target price points to a potential upside of 20.16% from the stock’s previous close.

ALNY has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price objective (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Chardan Capital restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, September 11th. Nomura assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 14th. They set a “reduce” rating and a $56.00 price target on the stock. ValuEngine raised shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, Instinet assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Friday, September 15th. They set a “reduce” rating and a $56.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. Alnylam Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $94.33.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 5.5120% on Thursday, reaching $123.9661. 693,065 shares of the company were exchanged. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $124.64. The stock’s 50-day moving average is $81.14 and its 200 day moving average is $69.12. The firm’s market capitalization is $11.37 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm’s revenue for the quarter was up 82.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.05) EPS. On average, analysts forecast that Alnylam Pharmaceuticals will post ($5.19) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Earns Buy Rating from Ladenburg Thalmann Financial Services” was published by BBNS and is the sole property of of BBNS. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://baseballnewssource.com/markets/alnylam-pharmaceuticals-inc-alny-rating-reiterated-by-ladenburg-thalmann-financial-services/1668329.html.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at $16,539,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Broadfin Capital LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $14,453,000. Verition Fund Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $1,060,000. The Manufacturers Life Insurance Company increased its holdings in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares in the last quarter. EcoR1 Capital LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $831,000. Finally, BlueCrest Capital Management Ltd acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $1,304,000. 94.25% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1


Leave a Reply

 
© 2006-2017 BBNS.